MaxCellLife 24/7 Immune Supplement has been Reported Effective for COVID-19, Colds and Flu, with 90% Reduction in COVID-19 Virus Infectivity Additionally Reported Through Independent University Research...
90% Reduction in COVID-19 Virus Infectivity Reported Through Independent University Research Study NEW YORK, NY / ACCESSWIRE / April 26, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that Immunitor,...
MaxCellLife MIND, a Proprietary M.Vaccae and Magnesium Compound, targets the Multi-Billion Anxiety, Stress and Depression Market NEW YORK, NY / ACCESSWIRE / April 8, 2021 / KEY CAPITAL CORPORATION (OTC...
Jennifer Reilly appointed Marketing Director to Lead MaxCellLife.com Launch NEW YORK, NY / ACCESSWIRE / April 7, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises the Company is launching https://MaxCellLife.com...
Therapeutic Cancer Vaccines - Key Capital Reports Progress and Development Priority NEW YORK, NY / ACCESSWIRE / March 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises the following to clarify...
Patented Immunitor Oral Pill Platform Intellectual Property Optimizes M.Vaccae Supplement and Ionic Magnesium Delivery to Immune System NEW YORK, NY / ACCESSWIRE / March 12, 2021 / KEY CAPITAL CORPORATION...
Multiple Human Clinical Trials Have Demonstrated Unprecedented Success in Cancers, Including HCC Liver Cancer, Vascular and Other Diseases, and Viruses NEW YORK, NY / ACCESSWIRE / March 3, 2021 / KEY CAPITAL...
Full Patent for Immunitor issued in China and EU Claims being re-filed NEW YORK, NY / ACCESSWIRE / February 18, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC) advises that it continues to work with Immunitor,...